U.S.) by senior researcher Junhua Austin Wei, targeting cost-competitive CMC by using a high char yield preceramic resin with functionalized ceramic particles to eliminate the infiltration step which ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi (durvalumab) for approval in the European Union (EU) as a single agent for ...

AstraZeneca AZN announced that CHMP has recommended approval for its blockbuster cancer drug Imfinzi (durvalumab) as a monotherapy for treating limited-stage small cell lung cancer (LS-SCLC ...

AstraZeneca, a global, science-led biopharmaceutical company, announced that its Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of ...

The new indication adds to Imfinzi's FDA-approved indications in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which have helped drive sales of the PD-L1 inhibitor to $1.3 ...

After a setback in a trial of Imfinzi in early non-small cell lung cancer (NSCLC) last year, AstraZeneca has clawed back some ground with a positive result in small-cell lung cancer (SCLC), a less ...

AZ believes the unpaid importation taxes stem from its immunotherapy duo Imfinzi and Imjudo, which can be used together to treat liver cancer. The indication has not been approved in mainland China.

AstraZeneca’s Imfinzi minimised mortality risk by 27% against a placebo. Credit: © AstraZeneca 2025. The European Medicines Agency’s Committee for Medicinal ...

(IN BRIEF) AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for approval as a ...